Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details)

v3.24.0.1
Basis of Presentation and Significant Accounting Policies - Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 21, 2022
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Intangible assets, net        
Impairment of intangible asset     $ 14,253  
Ebopiprant IP        
Intangible assets, net        
Estimated useful life of intangible asset 17 years      
Impairment of intangible asset     $ 14,253  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income     Impairment charges (Note 4, Note 5)  
ObsEva, Organon | License Agreement | Ebopiprant IP        
Intangible assets, net        
Impairment of intangible asset   $ 14,200 $ 14,200 $ 0
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income   Impairment charges (Note 4, Note 5) Impairment charges (Note 4, Note 5)